Making Daily Headlines · Page 3
FDA Adds an Eye Risk to the Miracle Drug Sales Pitch
· New York time
The Food and Drug Administration has found evidence of a potential increased risk of a rare eye condition linked to GLP-1 drugs used for weight management and diabetes, including medicines such as Wegovy and Zepbound. The finding adds a safety consideration to a class of treatments that has attracted enormous public attention. The agency's finding concerns a potential increased risk of a rare condition. It is not a claim that everyone taking these medicines will experience vision loss. The benefits and risks of any treatment depend on individual circumstances, and monitoring can reveal questions that deserve attention even when an outcome is uncommon. The development also exposes a gap between the public conversation about popular drugs and the work of assessing them. Advertising and celebrity discussion favor dramatic transformations and simple conclusions. Safety monitoring deals in evidence, uncertainty and the less glamorous task of identifying possible harms alongside benefits. A treatment can be useful and still have risks worth examining. That is a difficult message for a culture that prefers every medical story to fit into one of two boxes, miracle or catastrophe. The FDA has supplied a third box, labeled Read the Evidence, which is less marketable but considerably more useful.
Read this story in the full newspaper →Satire. Not factual reporting. Read the original reporting from the linked publishers.